Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat in Unresectable Hepatocellular Carcinoma
NCT00321594Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2006
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of belinostat in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoints: Dose-limiting Toxicity, Maximum Tolerated Dose and 1 more. Started May 2006; status: completed.
02
Drugs
belinostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00321594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321594.